The neonatal Fc receptor blocker nipocalimab exhibited significant improvement over placebo in systemic lupus erythematosus ...

Please provide your email address to receive an email when new articles are posted on . Blood dendritic cell antigen 2 and neonatal fragment crystallizable receptor are two novel strategies in lupus ...

In the ever changing biotherapeutics landscape, antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) success hinges on more than simply antigen recognition. While the Fab region controls ...

Autoimmune drug development increasingly recognizes that the Fc-FcR axis is more than an effector mechanism; it is a controllable immunological node that bridges humoral and cellular responses. This ...

Nipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic ...